2 results match your criteria: "Osteoncology and Rare Tumor Center (CDO-TR)[Affiliation]"
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.
Eur J Cancer
September 2024
Osteoncology and Rare Tumor Center (CDO-TR), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Background: Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies.
View Article and Find Full Text PDFTargeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET).
Diagnostics (Basel)
April 2023
Department of Medical or Surgical Sciences, University of Bologna, 40126 Bologna, Italy.
Article Synopsis
- Grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET) are not well understood regarding their molecular characteristics and treatment responses, prompting a study on their effectiveness with specific chemotherapy regimens.
- Out of 49 patients in the chemotherapy cohort, those treated with FOLFOX/XELOX showed an objective response rate of 38.2% and median overall survival of 30.0 months, while a Ki67 index of 40% or higher was linked to poorer outcomes.
- The next-generation sequencing (NGS) of 13 cases revealed that the mutation patterns in G3 NETs resemble those found in well-differentiated neuroendocrine tumors rather than neuro